Oncimmune Holdings plc (LON:ONC – Get Free Report) fell 17.7% on Monday . The company traded as low as GBX 18.10 ($0.24) and last traded at GBX 18.10 ($0.24). 117,187 shares changed hands during mid-day trading, an increase of 22% from the average session volume of 96,160 shares. The stock had previously closed at GBX 22 ($0.29).
Oncimmune Stock Performance
The stock has a market cap of £13.42 million, a P/E ratio of -703.33 and a beta of 1.19. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 806.85. The business has a 50 day moving average price of GBX 14.13 and a two-hundred day moving average price of GBX 17.92.
Oncimmune Company Profile
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.
Featured Stories
- Five stocks we like better than Oncimmune
- 3 Best Fintech Stocks for a Portfolio Boost
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- High Dividend REITs: Are They an Ideal Way to Diversify?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Energy and Oil Stocks Explained
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.
